Ultimately, the adoption of precision medicine strategies—guided by biomarkers that reflect the dominant functional role of the CXCL12/CXCR4 axis in individual patients—may be critical for realizing the full therapeutic potential of targeting this pathway in ALI/ARDS. This evidence concerns the gene CXCL12 and acute respiratory distress syndrome.